Triplet therapy effective for metastatic prostate cancer subset regardless of disease volume
Treatment intensification with darolutamide plus androgen deprivation therapy and docetaxel improved OS among men with metastatic hormone-sensitive prostate cancer regardless of disease volume or risk, according to study results.The benefits of early treatment intensification appeared consistent among men with high-volume or low-volume disease, as well as those with high-risk or low-risk disease,